Obesità sarcopenica: dal fenotipo clinico alla qualità della perdita di peso nel diabete di tipo 2
Il Diabete · 30.10.2026 · 38 (3)
DOI: 10.30682/ildia2603a ↗Kurz gefasst
Fachartikel in der Zeitschrift Il Diabete, online erschienen am 30.10.2026. Verfasst von Sebastiano Squatrito.
Abstract (Originalsprache)
Sarcopenic obesity (SO) is characterised by the coexistence of excess adiposity and impaired skeletal muscle mass and function. It is increasingly relevant in diabetology because type 2 diabetes mellitus (T2DM), ageing, physical inactivity, chronic low-grade inflammation and insulin resistance converge on common pathways that promote both fat accumulation and progressive deterioration of muscle quality. The 2022 ESPEN-EASO consensus provides a clinically useful framework based on screening, assessment of muscle function, confirmation of altered body composition and staging according to the presence of complications. In people with diabetes, recent evidence suggests that SO affects approximately one in four adults, although prevalence varies substantially with diagnostic criteria and setting. SO is associated with poorer physical performance, greater disability and frailty and a higher cardiometabolic risk. Management should therefore move beyond body-weight reduction alone and target the quality of weight loss. Nutritional treatment requires an individualised energy deficit while ensuring adequate protein and micronutrient intake; progressive resistance exercise is the cornerstone for preserving or improving strength and functional capacity. The widespread use of GLP-1 receptor agonists and incretin agonists has made monitoring of lean mass, dietary adequacy and physical function particularly relevant, especially in older adults and in patients undergoing rapid or substantial weight loss. A practical diabetology pathway should integrate anthropometry, muscle strength, body composition when available, nutritional assessment and repeated functional measures. This review summarises current concepts on definition, epidemiology, pathophysiology, diagnosis, prognosis and treatment of SO, with particular emphasis on T2DM and on muscle-preserving strategies during modern obesity pharmacotherapy.
Zitieren
APA
Squatrito, S. (2026). Obesità sarcopenica: dal fenotipo clinico alla qualità della perdita di peso nel diabete di tipo 2. Il Diabete, 38(3). https://doi.org/10.30682/ildia2603a
Vancouver
Squatrito S. Obesità sarcopenica: dal fenotipo clinico alla qualità della perdita di peso nel diabete di tipo 2. Il Diabete. 2026;38(3). doi:10.30682/ildia2603a
BibTeX
@article{Squatrito2026,
author = {Squatrito, Sebastiano},
title = {Obesità sarcopenica: dal fenotipo clinico alla qualità della perdita di peso nel diabete di tipo 2},
journal = {Il Diabete},
year = {2026},
volume = {38},
number = {3},
doi = {10.30682/ildia2603a}
}
EUVIMED